RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California and currently employs 0 full-time employees. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Follow-Up Questions
RetinalGenix Technologies Inc의 CEO는 누구입니까?
Dr. Jerry Katzman은 2018부터 회사에 합류한 RetinalGenix Technologies Inc의 President입니다.
RTGN 주식의 가격 성능은 어떻습니까?
RTGN의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
RetinalGenix Technologies Inc의 주요 사업 주제나 업종은 무엇입니까?
RetinalGenix Technologies Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
